Using metagenomics, Liu and colleagues demonstrated that dysbiosis accelerated prostate cancer progression through upregulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1), a key enzyme in the phospholipid remodeling pathway (Liu et al., 2021). The gene discussed is LPCAT1; the disease is Familial prostate cancer.